163 related articles for article (PubMed ID: 12431495)
21. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
22. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Pontrelli L; Parris W; Adeli K; Cheung RC
Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
[TBL] [Abstract][Full Text] [Related]
23. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Nawrocki JW; Weiss SR; Davidson MH; Sprecher DL; Schwartz SL; Lupien PJ; Jones PH; Haber HE; Black DM
Arterioscler Thromb Vasc Biol; 1995 May; 15(5):678-82. PubMed ID: 7749881
[TBL] [Abstract][Full Text] [Related]
24. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
[TBL] [Abstract][Full Text] [Related]
25. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.
Bakker-Arkema RG; Best J; Fayyad R; Heinonen TM; Marais AD; Nawrocki JW; Black DM
Atherosclerosis; 1997 May; 131(1):17-23. PubMed ID: 9180240
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
[TBL] [Abstract][Full Text] [Related]
27. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
Boquist S; Karpe F; Danell-Toverud K; Hamsten A
Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
29. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
[TBL] [Abstract][Full Text] [Related]
31. Rhabdomyolysis with concurrent atorvastatin and diltiazem.
Lewin JJ; Nappi JM; Taylor MH
Ann Pharmacother; 2002 Oct; 36(10):1546-9. PubMed ID: 12243603
[TBL] [Abstract][Full Text] [Related]
32. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
[TBL] [Abstract][Full Text] [Related]
33. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
Marais AD; Firth JC; Bateman ME; Byrnes P; Martens C; Mountney J
Arterioscler Thromb Vasc Biol; 1997 Aug; 17(8):1527-31. PubMed ID: 9301631
[TBL] [Abstract][Full Text] [Related]
35. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study.
Heinonen TM; Stein E; Weiss SR; McKenney JM; Davidson M; Shurzinske L; Black DM
Clin Ther; 1996; 18(5):853-63. PubMed ID: 8930429
[TBL] [Abstract][Full Text] [Related]
36. Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.
Krasuski RA; Doeppenschmidt D; Henry JS; Smith PB; Adinaro J; Beck R; Thompson CM
Mayo Clin Proc; 2005 Sep; 80(9):1163-8. PubMed ID: 16178496
[TBL] [Abstract][Full Text] [Related]
37. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
38. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.
Bernini F; Poli A; Paoletti R
Cardiovasc Drugs Ther; 2001; 15(3):211-8. PubMed ID: 11713888
[TBL] [Abstract][Full Text] [Related]
39. Comparison of statins in hypertriglyceridemia.
Stein EA; Lane M; Laskarzewski P
Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
[TBL] [Abstract][Full Text] [Related]
40. Rhabdomyolysis after taking atorvastatin with gemfibrozil.
Duell PB; Connor WE; Illingworth DR
Am J Cardiol; 1998 Feb; 81(3):368-9. PubMed ID: 9468088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
